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THE effects of platelet activating factor (PAF) on eicosa-
noid release during endotoxic shock was investigated in
anaesthetized pigs receiving 5/,g kg
-1 Escherichia coil
endotoxin (LPS) into the superior mesenteric artery over a
60 rain period, by measuring plasma levels of a variety of
mediators. Fifteen of the 31 animals infused with LPS and
not treated with BN 52021, a PAF receptor antagonist,
died within 30 min after the commencement of LPS
infusion (non-survivors), while the other 16 survived the
experimental period of 3 h, though in a state of shock
(survivors). No alterations were observed in plasma con-
centrations of eicosanoids in the non-survivors. A signifi-
cant, though transient, increase in eicosanoid concentra-
tions occurred only in the survivors. Treatment with BN
52021 (4 mg kg-1, i.v.) injected 5 min prior to LPS infu-
sion, failed to exert any effect on the survival rate. How-
ever, pretreatment with BN 52021 prevented circulatory
collapse in the survivors and reduced the concentration of
cyclooxygenase enzyme products, without affecting LTB
release. Exogenous administration of PAF (0.01/g kg-1)
caused hypotension and increased TXB2 levels although
6-keto PGFI and LTB concentrations were unchanged.
The data suggest that prostanoid formation may be sec-
ondary to PAF release in circulatory collapse evoked by
LPS infusion in survivors, and give further support to the
suggestion that PAF prostanoid interaction is important
during endotoxic shock. However, their role in early death
seems to be negligible, indicating the importance of other
mediators.
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Introduction
Effective treatment for the cardiopulmonary
derangements characteristic of septic shock is
lacking, although sepsis is of major clinical
importance and associated with a high morbidity
and mortality. 1’2 Sufficient evidence has accumu-
lated which suggests that lipid mediators (platelet
activating factor and eicosanoids) are important
mediators of endotoxic or septic shock.
3 There are
at least three major lines of evidence supporting a
role for lipid mediators in endotoxic/septic shock.
Products of the arachidonic acid cascade and PAF
can be detected in the circulation at concentrations
sufficiently high to be responsible for many of the
events observed during endotoxic/septic shock.
-v6
Administration of either eicosanoids or PAF into
experimental animals produces pathophysiological
events characteristic of the state of shock. 3’5’7’8
Pharmacological studies have shown that appropri-
ate synthesis inhibitors or receptor antagonists of
lipid mediators are capable of modifying the course
of endotoxic/septic shock. 3’s’6’8’9 Although any of
these respective observations does not by itself
provide proof for a cause-effect relationship, the
data taken together suggest that these lipid
mediators may play an important role in the
development and maintenance of endotoxic/septic
shock. Furthermore, evidence is rapidly accumula-
ting that there may be an intimate relationship
between PAF and eicosanoids, and some of the
effects of PAF may be mediated via the
eicosanoids. 1--12 For example, a mediator role for
thromboxane has been proposed in PAF-induced
cardiac failure-
and airway hyperresponsiveness.
14
Leukotrienes have been proposed to mediate, in
part, pulmonary vasoconstriction and oedema
formation evoked by PAF.s Both prostanoids and
leukotrienes have been demonstrated to mediate
PAF-induced bowel necrosis.
6
Based on these and our previous findings, we
hypothesized that an intimate relationship between
PAF and eicosanoids may exist in endotoxic shock,
too. The purpose of the present work was to
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investigate whether eicosanoid formation is second-
ary to PAF release and to study the role of
eicosanoids in mediating PAF induced haemodyna-
mic events during endotoxic shock in anaesthetized
pigs.
Materials and Methods
Animals: After an overnight fast, young female
Yorkshire pigs (body weight: 20-24 kg, age: 12-16
weeks) were initially anaesthetized with i.m.
injections of ketamine (20rag kg -1) and mid-
azolam (0.25 mg kg -1) as well as atropine (0.05
mg kg-1). The anaesthesia was maintained
throughout the experiment with i.v. sodium
pentobarbitone (20 mg kg
--1 bolus followed by a
20 mg kg- h-
infusion). A tracheostomy was
performed and the animals were ventilated with
intermittent positive pressure (Bear 2E adult
wlume ventilator, Lameris, The Netherlands).
Respiratory rate, tidal volume and oxygen to air
ratio were adjusted to keep arterial blood gases
within normal ranges: pH 7.35--7.45, 90 < p().
mmHg < 150, 35 < pCOp. mmHg < 45. The tem-
perature of the animals was maintained at around
38(; by use of an electric blanket. Catheters were
placed via femoral vessels into the aorta and
pulmonary artery (Swan-Ganz 7F catheter). A
midline laparotomy was performed and the superior
mesenteric artery was exposed. A needle (0.5 mm
external diameter) connected to a suitable poly-
ethylene tube was inserted directly into the superior
mesenteric artery for infusion of LPS or normal
saline. Another catheter was inserted into the
superior mesenteric vein through a branch vein for
collecting blood samples and measurement of mean
portal venous pressure. The abdomen was then
closed and a Ringer-lactate infusion at a rate of
4 ml kg-1 h- was started. The animals were
allowed to remain undisturbed for 30 min to ensure
haemodynamic stability. Mean arterial blood
pressure, mean pulmonary arterial pressure and
mean portal venous pressure were continuously
monitored by electromanometers with Statham
P23db strai gauges (Hato Rey, PR). Cardiac output
was determined intermittently by thermodilution
(WTI Computer, The Netherlands). The determina-
tions were performed in triplicate and the results
averaged.
Assq for plasma levels of TXBe, 6-keto PGtV and ll_’B4
Blood samples for eicosanoid determinations were
obtained from the superior mesenteric vein. The
samples were collected into iced polypropylene
tubes containing 20/,1 of heparin (5000 U m1-1
Thromboquline c">, ()rganon, ()ss, The Nether-
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lands) and 50/,1 of indomethacin (0.1 mg ml-
in
0.1 M phosphate buffer pH 8). After centrifugation
plasma was decanted and stored at -70C until
extraction of eicosanoids, while the red blood cells
were suspended in 0.9% saline and were iniected
back after each blood collection. Details of the
radioimmunoassay (RIA) for eicosanoid determina-
tion have been reported previously.r
Experimental protocols"
Group I" Sham operated. Five animals were
prepared as described above, except that instead of
I,PS, normal saline was infused into the superior
mesenteric artery. Ten ml of blood was collected
from the superior mesenteric vein for eicosanoid
determination.
Group II" Sham operated, BN 52021 treated.
Four animals were prepared as for Group I.
Following control measurements and blood collec-
tions BN 52021 (4 mg kg -1) was in}ected
intravenously 10 min before the second blood
collection. Blood was collected as in Group III.
Group III" LPS-induced shock. Thirty-one pigs
were infused with 5/g kg-
Escherichia coli LPS
(()111 B4, Serva) into the superior mesenteric artery
over a 60 min period and the animals were observed
for an additional 120 min period. Blood was
collected from the superior mesenteric vein for
eicosanoid measurements 10 min before, and 15, 30
and 60 min after starting LPS infusion, and 60 and
120 min after I,PS infusion.
Group IV" BN 52021 pretreated, LPS infused. A
protocol similar to that just described was followed
in 13 animals, except that BN 52021 (4 mg kg
-1
i.v.) was administered 5 min before the LPS
infusion was started.
Group V" Injection of PAF into the superior
mesenteric vein. In four pigs PAF (1-
O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine,
Sigma Chemicals, Deisenhofen, Germany) (0.01 /g
kg-) was injected into the superior mesenteric vein
over 1 min in the absence and presence ofBN 52021
(4 mg kg -l) administered 5 min prior to PAF
injection. Hypotensive response to exogenous PAF
and eicosanoid release were tested 10 min before,
and 5 min and 60 min after PAF injection.
Statistical analysis" All values are expressed as
means-+-SEM. The data were evaluated by a
non-parametric two-way analysis of variance
(Friedman test) followed by the Wilcoxon--Wilcox
test to identify differences between measurements
performed at the control period and at different
times during and after LPS infusion. The
Mann---Whitney U test was performed to evaluate
the differences between the groups. A p value of
0.05 or less was considered statistically significant
for all tests.PAF and eicosanoids in endotoxic shock
Results
Sham operated animals: In sham operated animals
systemic haemodynamic variables (Figure 1) and
eicosanoid levels (Figure 2) were stable during the
experiment. Similarly, haemodynamic variables and
eicosanoid levels remained stable during the
experiments in sham operated animals treated with
BN 52021 (Figures 1 and 2).
Animal survival: A total of 44 pigs received LPS
infusion for 60 min (Groups III and IV). Group II1
consisted of 31 animals which received LPS only.
Fifteen of these 31 animals died at, or close to, 30
rain after the start of LPS infusion (non-surviwrs).
The remaining 16 animals survived the experi-
mental period of 3 h (i.e. 2 h after the termination
of LPS infusion) though in a state of profound
shock (survivors). Treatment with 4 mg kg
--1 of
BN 52021, injected 5 min prior to I,PS infusion,
failed to exert any effect on the survival rate. Seven
of the 13 pigs treated with PAF receptor antagonist
died at about 30 min, similar to animals in the LPS
treated group. However, the group of survivors
treated with BN 52021 resulted in maintenance of
most of the parameters at a level comparable to that
before I,PS infusion.
Systemic haemodynamics (Figure 1)" In Group III pigs
not surviving the LPS infusion, mean arterial blood
pressure dropped to 29-4-2 mmHg, mean portal
venous pressure increased to 13.5-4-1.5 mmHg.
Mean pulmonary arterial pressure increased to
44.5 _--t-4 mmHg and cardiac output decreased to
{).93-+-0.11 1/min, shortly before death (30 min
after the start of I,PS infusion). In BN 52021
pretreated non-survivors similar effects were
observed.
In pigs surviving the ImPS infusion, mean arterial
blood pressure gradually decreased to 59-F 5.5
mmHg at the end of the 3 h observation period (2 h
after the termination of LPS infusion); mean portal
venous pressure first increased to peak values at 30
min before decreasing slightly but remaining higher
than the baseline values; mean pulmonary arterial
pressure increased to a peak value at 30 min before
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FIG. 1. Effect of BN 52021 (4 mg kg pretreatment on systemic haemodynamics in pigs receiving endotoxic (LPS) infusion into the superior mesenteric
artery. Arrows indicate the time for administration of LPS. Open triangle indicates sham operated animals (n 5). Closed triangle indicates sham
operated, BN 52021 pretreated animals (n 4). Open circle indicates those animals that died within 30 min after starting LPS infusion (non-survivors,
n 15). Closed circle indicates those animals that survived the observation period of 3 h after starting LPS infusion (survivors, n 16). Open square
indicates BN 52021 pretreated (5 min prior to LPS infusion) non-survivors (n 7). Closed square indicates BN 52021 pretreated survivors (n 6).
Values are means with SEM shown by vertical bars. Abbreviations: MABP, mean arterial blood pressure; MPVP, mean portal venous pressure; MPAP,
mean pulmonary arterial pressure; CO, cardiac output. *p < 0.05 value was obtained by two-way analysis of variance (Friedman test) followed by
Wilcoxon--Wilcox test for multiple comparisons, control (t 0 min), control vs. 30 min etc.
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FIG. 2. Effect of BN 52021 pretreatment on plasma levels of eicosanoids in superior mesenteric vein in pigs receiving endotoxin (LPS) infusion
into the superior mesenteric artery. Ordinate" logarithmic scale of changes in concentrations of leukotriene B4 (LTB4), 6-keto prostaglandin
FI (6-keto PGFI=) and thromboxane B (TXB2). Other details as in Figure 1.
decreasing to the baseline at the end of the 3 h
observation period; cardiac output first decreased
rapidly (15-30 min after the start of LPS infusion)
and, after a transient increase, decreased again
gradually to about 35% of the baseline value (from
the end of LPS infusion until the end of the
observation period).
In BN 52021 pretreated survivors mean arterial
blood pressure was preserved. At 180 min, mean
arterial blood pressure in BN 52021 pretreated
survivors (n 6) was 105_ 5 mmHg whereas in
LPS treated survivors (n-16) the MABP was
59 + 5.5 mmHg, p < 0.01. BN 52021 did not affect
the duration or the magnitude of the increase in
mean portal venous pressure and mean pulmonary
arterial pressure during or after LPS infusion.
Though cardiac output was markedly reduced in
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BN 52021 pretreated survivors by the end of
the experiment, it was still higher than in LPS
infused survivors (1.5 -+- 0.1 1/min, n 6 vs. 1.0
0.1 l/rain, n 9, p < 0.05).
Mediator release (Figure 2): Plasma concentration of
TXB2 in the superior mesenteric vein increased
markedly, but only for a short time, during LPS
infusion in survivors (n 5). Similarly a transient,
but less marked increase was detected in 6-keto
PGFI= concentrations of the superior mesenteric
vein in survivors (n 5). The increase in TXB2
concentrations started 30 rain earlier than in 6-keto
PGFI elevation. In survivors, the plasma con-
centrations of LTB4 also showed an increase in
superior mesenteric vein (n 5). However, LTB4
production was still elevated, even when thePAF and eicosanoids in endotoxic shock
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FIG. 3. Effect of BN 52021 (4 mg kg -1) pretreatment on the hypotensive
response to exogenous platelet activating factor (PAF) in anaesthetized
pigs (n=4). PAF (0.01#gkg -1) was injected into the superior
mesenteric vein over min. Arrows indicate the time for administration
of either PAF or BN 52021, as appropriate. Other details as in Figure 1.
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FIG. 4. Effect of BN 52021 (4 mg kg -1) on the plasma level of
thromboxane B2 (TXB2) in the superior mesenteric vein after
administration of exogenous platelet-activating factor (PAF) in anaesthe-
tized pigs (n 4). PAF (0.01 /g kg -1) was injected into the superior
mesenteric vein over min. Arrows indicate the time for admin-
istration of either PAF or BN 52021, as appropriate. Other details as in
Figure 1.
concentrations of TXB2 and 6-keto PGFI had
returned to baseline. In contrast, no changes were
found in eicosanoid concentrations in LPS infused
non-survivors (n 5).
In BN 52021 pretreated survivors the plasma
concentration of TXB2 was markedly reduced but
remained slightly elevated (n 6). PAF receptor
antagonism had minimal effects on 6-keto PGFI=
and did not affect LTB4 synthesis observed in LPS
treated survivors. A correlation was found between
mean pulmonary arterial blood pressure and the
ratio of TXB2 to 6-keto PGF= in BN 52021
pretreated survivors (r 0.5542, n 25, p < 0.005)
as well as in LPS infused survivors (r 0.5738,
n 24, p < 0.001). No changes were found in
eicosanoids in BN 52021 pretreated non-survivors
(n 7).
Effects of exogenous PAF and the eJfectiveness ofBN 52021
treatment on exogenous PAF (Figures 3 to 5) Administra-
tion of 0.01 #g kg-
of PAF into the superior
mesenteric vein over 1 min reduced mean arterial
blood pressure from 101 -k 10 mmHg to 53 10
mmHg in the absence, and from 105 +__ 8 mmHg to
96-+-18 mmHg in the presence, of BN 52021 (4
mg kg -1) injected 5 min prior to PAF administra-
tion (n 4, p < 0.05, Figure 3). This dose of PAF
elevated plasma concentration of TXB2 from
90-+-15 pg ml-
to 370-+-75 pg m1-1 (n=4,
p < 0.05). This effect of PAF on thromboxane
release was completely abolished by pretreatment
with 4 mg kg-
of BN 52021 (n- 4, Figure 4).
Administration of 0.01/g kg
-I of PAF into the
superior mesenteric vein had no effect on
plasma concentrations of 6-keto PGF and LTB4
at time points observed (n 4, Figure 5).
Discussion
The findings in the present study are: (a) the
non-survivors following LPS infusion showed
marked haemodynamic alterations and no changes
in release of eicosanoids; (b) the animals surviving
LPS infusion remained in a state of shock and
presented a sequential release of eicosanoids; (c)
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FIG. 5. Effect of exogenous platelet activating factor (PAF) on the plasma
levels of leukotriene B4 (LTB,) and 6-keto prostaglandin F= (6-keto
PGF) in the superior mesenteric vein in anaesthetized pigs (n 4). PAF
(0.01 #g kg -1) was injected into the superior mesenteric vein over min.
Other details as in Figure 1.
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treatment with PAF receptor antagonist BN 52021
(4 mg kg -1) injected 5 min prior to LPS infusion,
failed to exert any effect on the survival rate; (d) in
BN 52021 pretreated survivors all circulatory
parameters studies were improved, and thrombox-
ane synthesis/release was markedly attenuated,
whereas prostacyclin production was slightly
modified and LTB4 release was not affected; (e)
exogenous administration of PAF (0.01 /g kg -l)
produced hypotension and an increase in the
concentration ofTXB2 without any modification on
the concentrations of 6-keto PGFI and LTB4; (f)
BN 52021 (4 mg kg -1) pretreatment completely
prevented the effects of exogenous PAF on blood
pressure and thromboxane production.
Low amounts of LPS infused into the superior
mesenteric artery provided a unique model for
studying various changes induced by LPS infusion
in surviving and non-surviving pigs as we have
previously reported. 4’5’9 In the present work we
were concerned to what extent death and endotoxic
shock, induced by LPS infusion, are related to
changes in lipid mediators activity.
Treatment with the PAF receptor antagonist BN
52021 5 min prior to the start of LPS administration
did not prevent death and failed to modify the
survival rate. This is understandable since the
release of PAF has been observed only in surviving
animals but not in non-survivors, thereby ruling
out the role of endogenous PAF in causing death.
Similarly, no changes were observed in eicosanoid
release for non-survivors; consequently, their role
in the early death also seems to be negligible. The
major change detected in non-survivors was a
marked increase in TNF release that was not
affected by BN 52021 treatment. 5’1s Thus it seems
likely that death caused by LPS infusion is due to
a marked increase in TNF release. This assumption
is also supported by the findings that the amount
of TNF released in survivors following LPS
infusion was much less than in non-survivors. TM The
exact reason for the lack of PAF and eicosanoid
release in non-survivors is not yet clear. It might
be that TNF, released in large quantities during
rapid death, has a destructive effect on the cells able
to synthesize PAF and eicosanoids as our in vivo data
and the in vitro data obtained by others indicate.5’9
In contrast to the lack of involvement of PAF
and eicosanoids in LPS induced death, the present
and our previous4’5’9 results indicate that release of
PAF and eicosanoids observed during LPS infusion
may play a role in the development of endotoxic
shock seen in survivors. Most of the critical events
occurred at 30 min of endotoxaemia, a time point
which coincides with the marked increase in
concentrations of PAF and TXB2 in the superior
mesenteric vein. It should be remembered that the
peak in the release of PAF and thromboxane
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preceded the maximum in TNF production in LPS
treated survivors. It might be that TNF, released
in large quantities during rapid death, has a
destructive effect on the cells able to synthesize
eicosanoids.
9
In addition, BN 52021 treatment significantly
attenuated both the magnitude and duration of
haemodynamic changes in survivors. Mean arterial
blood pressure remained stable, while cardiac out-
put decreased but remained still higher than in LPS
treated survivors. On the other hand, BN 52021 had
no effect on the elevated portal and pulmonary
pressures, while the thromboxane synthesis/release
was markedly attenuated, indicating that mediators
other than PAF and thromboxane might be in-
volved. Another explanation may be that the bal-
ance between thromboxane and prostacyclin might
be more important than the change in thromboxane
and prostacyclin levels in itself. Considerable evi-
dence exists that the thromboxane to prostacyclin
ratio is a critical factor in coronary artery disease
2
as well as in mesenteric ischaemia/reperfusion-
induced shock
21 and endotoxic shock.4 However, it
should be kept in mind that the concentrations at
which these eicosanoids exert opposite effects are
unknown. Moreover, it is also important that the
concentrations of TXB2 and 6-keto PGFI do not
reflect exactly the release of thromboxane and pros-
tacyclin, but only the net result of their release,
degradation and renal and hepatic clearance.
Nevertheless, present results demonstrate a correla-
tion between TXB2 to 6-keto PGF ratio and
pulmonary arterial pressure while this correlation
was not observed when absolute concentrations of
these compounds were used. One should remember
that in the present investigations BN 52021 altered
only slightly the prostacyclin production while
markedly attenuated the thromboxane production
resulting in an imbalance between thromboxane and
prostacyclin in favour of prostacyclin, which is
22 thought to be beneficial in different shock states.
The exact benefits of a PAF receptor antagonist on
endotoxic shock are unclear; however, present
results indicate that they may be related to the
effects of BN 52021 on prostanoid synthesis.
The rationale for evaluating the effects of a PAF
receptor antagonist on the eicosanoid products of
arachidonic acid is that these lipid mediators (i.e.
PAF and eicosanoids) have been shown to interact
with each other under several conditions.
s-6 The
injection of PAF into an isolated gastric perfusion
model significantly increased the production of
thromboxane and prostacyclin which resulted in
vasoconstriction.
23 The PAF receptor antagonist,
BN 52021, not only reduced the vasoconstriction,
but also significantly inhibited PAF-induced eicosa-
noid release.
2 Acute circulatory collapse in dogs
from exogenous PAF administration is associatedPAF and eicosanoids in endotoxic shock
with the release of thromboxane and prostacyclin.
24
However, in the present experiment the hypo-
tensive response to exogenous PAF, injected into
the superior mesenteric vein, was only associated
with the increase in plasma concentration of TXB2.
No changes were observed in plasma concentra-
tions of 6-keto PGFI and LTB4 following
exogenous PAF administration. This discrepancy
might be attributable to either species differences or
differences in the doses and route of administration
of PAF (i.e. injection into the mesenteric vein in
the present study vs. injection into the femoral or
gastric vessels in the previous experiments).23’24 The
differences in the doses used may be one of the most
important explanations for the discrepancy between
the effects of exogenous PAF. Namely, low
concentrations of PAF (10-3-10
-1 M) induce the
conversion of arachidonic acid into mainly
prostanoids, while higher concentrations of PAF
(108-10
-5 M) increase leukotriene production via a
biphasic change in cyclic AMP level.
25 In the
present study the peak concentrations of PAF in
the mesenteric blood can be calculated as about
1000-1300 pg m1-15 These values are in the same
order of magnitude as those measured at 30 min of
endotoxaemia suggesting that the amount of PAF
formed during LPS infusion might be sufficient for
causing the observed changes in thromboxane
release. The maximum release of PAF and
thromboxane following LPS infusion occurred at
the same time and both preceded the peak in
6-keto-PGFl and LTB4 concentrations, suggesting
a dissociation in eicosanoid release evoked by
administration of exogenous PAF. Further evidence
for dissociation in eicosanoid release following PAF
injection might be the results with BN 52021. At a
concentration of 4 mg kg
-1 this drug inhibited
markedly thromboxane synthesis following en-
dotoxin in the experiments described, while PAF
receptor antagonism had minimal effects on
prostacyclin and leukotriene synthesis. These
observations of pig endotoxaemia are similar to
those reported in rat and dog endotoxaemia. 11’12
The exact reason, however, for the blocking effect
of BN 52021 on prostanoid production is not yet
clear. It is highly unlikely that BN 52021 acted as
a cyclooxygenase inhibitor, since it failed to affect
prostanoid formation in sham operated pigs.
Whether PAF and/or BN 52021 could modify phos-
pholipase A2 activity remains to be examined.
Taken together, the data in the present study
suggest that PAF stimulates the release of throm-
boxane, and PAF receptor antagonism has its major
effect on thromboxane production in endotoxaemia.
The findings of the present study give further
support to the notion that PAF and eicosanoids may
have an important interaction during endotoxic
shock. 1’11’12 In the past few years, it has become
increasingly apparent that a relationship exists
between PAF and eicosanoids.
1 Once released,
PAF and prostanoids may exert a wide range of
biological activities, like hypotension, haemocon-
tractions and activation of various cells,24’26’27
which, in turn, release other vasoactive mediators.
27
Our observation that the PAF receptor antagonist
prevented the prostanoid release is consistent and
supports the suggestion that PAF may serve as a
focal distributor of eicosanoids.
In conclusion, the present data suggest that
prostanoid formation is secondary to PAF release
and prostanoids may mediate and/or modulate the
haemodynamic effeccts ofPAF during LPS infusion
induced shock. However, their role in early
death seems to be negligible. It appears that
mediators other than PAF and eicosanoids are also
involved in the development of endotoxic shock.
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